Farnesoid X receptor agonist INT-787 exhibits high intestinal localization

被引：0

作者：

Burkey, Jennifer ^{[1
]}

Kansra, Sanjay ^{[1
]}

Macchiarulo, Antonio ^{[2
]}

Brouwer, Kenneth ^{[3
]}

Adorini, Luciano ^{[1
]}

Erickson, Mary ^{[1
]}

Pellicciari, Roberto ^{[4
]}

机构：

[1] Intercept Pharmaceut Inc, Morristown, NJ USA

[2] Univ Perugia, Dept Pharmaceut Sci, Perugia, Italy

[3] BioIVT, ADME TOX Div, Chapel Hill, NC USA

[4] TES Pharma Srl, Perugia, Italy

来源：

JOURNAL OF HEPATOLOGY | 2024年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

THU-316

引用

页码：S126 / S127

页数：2

共 50 条

[31] Intestinal microbiota-farnesoid X receptor axis in metabolic diseases
Zou, Bu
Yang, Wenling
Tang, Ying
Hou, Yangfeng
Tang, Tingting
Qu, Shunlin
CLINICA CHIMICA ACTA, 2020, 509 : 167 - 171
[32] Extending the Structure-Activity Relationship of Anthranilic Acid Derivatives As Farnesoid X Receptor Modulators: Development of a Highly Potent Partial Farnesoid X Receptor Agonist
Merk, Daniel
Lamers, Christina
Ahmad, Khalil
Gomez, Roberto Carrasco
Schneider, Gisbert
Steinhilber, Dieter
Schubert-Zsilavecz, Manfred
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (19) : 8035 - 8055
[33] EDP-305, A Novel and Potent Farnesoid X Receptor Agonist, Exhibits Favorable Anti-inflammatory and Anti-fibrotic Activity In Vitro
Li, Yang
Chau, Mary D.
Wang, Guoqiang
Or, Yat Sun
Jiang, Lijuan
HEPATOLOGY, 2016, 64 : 791A - 791A
[34] AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC
Kowdley, K. V.
Jones, D.
Luketic, V.
Chapman, R.
Burroughs, A.
Hirschfield, G.
Poupon, R.
Schramm, C.
Vincent, C.
Rust, C.
Pares, A.
Mason, A.
Sciacca, C.
Beecher-Jones, T.
Bohm, O.
Castelloe, E.
Pruzanski, M.
Shapiro, D.
JOURNAL OF HEPATOLOGY, 2011, 54 : S13 - S13
[35] Process Research and Impurity Control Strategy for Obeticholic Acid, a Farnesoid X Receptor Agonist
Feng, Wei-Dong
Zhuo, Song-Ming
Zhang, Fu-Li
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2019, 23 (09) : 1979 - 1989
[36] Intestinal Farnesoid X Receptor Activation by Pharmacologic Inhibition of the Organic Solute Transporter α-β
van de Wiel, Sandra M. W.
de Waart, D. Rudi
Elferink, Ronald P. J. Oude
van de Graaf, Stan F. J.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 2018, 5 (03): : 223 - 237
[37] Identification of isotschimgine as a novel farnesoid X receptor agonist with potency for the treatment of obesity in mice
Li, Yin
Chen, Hui
Ke, Zunli
Huang, Jinwen
Huang, Leilei
Yang, Baican
Fan, Shengjie
Huang, Cheng
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 521 (03) : 639 - 645
[38] A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia
Evans, Mark J.
Mahaney, Paige E.
Borges-Marcucci, Lisa
Lai, KehDih
Wang, Shuguang
Krueger, Julie A.
Gardell, Stephen J.
Huard, Christine
Martinez, Robert
Vlasuk, George P.
Harnish, Douglas C.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2009, 296 (03): : G543 - G552
[39] The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid
Walters, J. R. F.
Johnston, I. M.
Nolan, J. D.
Vassie, C.
Pruzanski, M. E.
Shapiro, D. A.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (01) : 54 - 64
[40] Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist
Epifano, Francesco
Genovese, Salvatore
Squires, E. James
Gray, Matthew A.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (09) : 3130 - 3135

← 1 2 3 4 5 →